SEOUL, South Korea, Feb. 13, 2025 — DAAN Biotherapeutics, a leading innovator in TCR-based therapies, has granted LigaChem Biosciences exclusive rights to a novel, tumor-targeting antibody. This agreement will advance the development and market launch of Antibody-Drug Conjugates (ADCs).

This collaboration allows LigaChem Biosciences to significantly progress its ADC development for patients with solid tumors, utilizing DAAN Biotherapeutics’ cutting-edge antibody technology and expertise in target discovery and antibody development.

DAAN Biotherapeutics has built a proprietary pipeline of antibodies targeting overexpressed tumor targets in solid cancers, achieved through a strategic partnership with OmniAb.

Byoung Chul Cho, MD, CEO of DAAN Biotherapeutics, commented, “We are committed to developing advanced antibodies for solid tumors and partnering with global pharmaceutical companies in the ADC field. Our goal extends beyond ADCs; we aim for global leadership in solid tumor-targeting T-cell engagers using our proprietary TACTIC (Tumor Targeting Conditionally Activated T Cell Engager) platform.”

SOURCE DAAN Biotherapeutics